| Symbol | MLYS |
|---|---|
| Name | MINERALYS THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 150 N. RADNOR CHESTER RD.,SUITE F200, RADNOR, Pennsylvania, 19087, United States |
| Telephone | 8883786240.0 |
| Fax | — |
| — | |
| Website | https://mineralystx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001933414 |
| Description | Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania. Additional info from NASDAQ: |
📋 Rodman David Malcom (Officer) plans to sell 14K shares of Mineralys Therapeutics, Inc. (at $26.48 each, total $372K) Filed: Aug 13, 2026 | ID: 000385
Read moreMineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Read moreFerguson James J. III 🟢 acquired 237.4K shares (1 derivative) of Mineralys Therapeutics, Inc. (MLYS) at $27.38 ($3.7M) Transaction Date: Aug 10, 2026 | Filing ID: 000120
Read moreRodman David Malcom 🟡 adjusted position in 2.2K shares (1 derivative) of Mineralys Therapeutics, Inc. (MLYS) at $27.09 Transaction Date: Aug 10, 2026 | Filing ID: 000118
Read moreNew Form 3 - Mineralys Therapeutics, Inc. <b>Filed:</b> 2026-08-12 <b>AccNo:</b> 0001933414-26-000119 <b>Size:</b> 14 KB
Read more(10% Negative) MINERALYS THERAPEUTICS, INC. (MLYS) Reports Q3 2026 Financial Results
Read moreMineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Read moreMineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Read more📋 Rodman David Malcom (Officer) plans to sell 2K shares of Mineralys Therapeutics, Inc. (at $27.09 each, total $59K) Filed: Aug 10, 2026 | ID: 000377
Read moreMineralys Therapeutics to Announce Second Quarter 2026 Financial Results and Host Conference Call on Tuesday, August 11, 2026
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06785454 | A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With … | Phase2 | Obstructive Sleep Apnea | Completed | 2025-02-28 | 2025-12-29 | ClinicalTrials.gov |
| NCT06150924 | Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter… | Phase2 | Chronic Kidney Disease | Completed | 2023-12-14 | 2025-04-23 | ClinicalTrials.gov |
| NCT06153693 | Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant… | Phase3 | Hypertension | Completed | 2023-11-22 | 2025-01-24 | ClinicalTrials.gov |
| NCT05968430 | Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability o… | Phase3 | Hypertension | Active_Not_Recruiting | 2023-07-14 | 2027-05-01 | ClinicalTrials.gov |
| NCT05769608 | A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncon… | Phase2 | Hypertension | Completed | 2023-03-13 | 2025-01-15 | ClinicalTrials.gov |
| NCT05001945 | Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hyper… | Phase2 | Hypertension, Renal | Completed | 2021-07-01 | 2022-10-07 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE3 | Hypertension | ACTIVE_NOT_RECRUITING | NCT05968430 |
| lorundrostat | Other | Phase PHASE3 | Hypertension | ACTIVE_NOT_RECRUITING | NCT05968430 |
| Placebo | Other | Phase PHASE3 | Hypertension | ACTIVE_NOT_RECRUITING | NCT05968430 |
| lorundrostat | Other | Phase PHASE3 | Hypertension | ACTIVE_NOT_RECRUITING | NCT05968430 |
| Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD | Other | Phase PHASE2 | Chronic Kidney Disease | COMPLETED | NCT06150924 |
| Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD | Other | Phase PHASE2 | Chronic Kidney Disease | COMPLETED | NCT06150924 |
| MLS-101 (Part II) | Other | Phase PHASE2 | Hypertension, Renal | COMPLETED | NCT05001945 |
| Placebo (Part II) | Other | Phase PHASE2 | Hypertension, Renal | COMPLETED | NCT05001945 |
| Placebo (Part I) | Other | Phase PHASE2 | Hypertension, Renal | COMPLETED | NCT05001945 |
| MLS-101 (Part I) | Other | Phase PHASE2 | Hypertension, Renal | COMPLETED | NCT05001945 |
| Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD | Other | Phase PHASE2 | Chronic Kidney Disease | COMPLETED | NCT06150924 |
| Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD | Other | Phase PHASE2 | Chronic Kidney Disease | COMPLETED | NCT06150924 |
| lorundrostat Dose 2 | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT06153693 |
| lorundrostat Dose 1 | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT06153693 |
| Placebo | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT06153693 |
| Placebo | Other | Phase PHASE2 | Obstructive Sleep Apnea | COMPLETED | NCT06785454 |
| Lorundrostat | Other | Phase PHASE2 | Obstructive Sleep Apnea | COMPLETED | NCT06785454 |
| lorundrostat Dose 2 | Other | Phase PHASE2 | Hypertension | COMPLETED | NCT05769608 |
| lorundrostat Dose 1 | Other | Phase PHASE2 | Hypertension | COMPLETED | NCT05769608 |
| Placebo | Other | Phase PHASE2 | Hypertension | COMPLETED | NCT05769608 |
| Placebo | Other | Phase PHASE3 | Hypertension | ACTIVE_NOT_RECRUITING | NCT05968430 |
| lorundrostat | Other | Phase PHASE3 | Hypertension | ACTIVE_NOT_RECRUITING | NCT05968430 |
| lorundrostat Dose 2 | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT06153693 |
| lorundrostat Dose 1 | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT06153693 |
| Placebo | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT06153693 |
| lorundrostat Dose 2 | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT06153693 |
| lorundrostat Dose 1 | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT06153693 |
| Placebo | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT06153693 |
| lorundrostat Dose 2 | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT06153693 |
| lorundrostat Dose 1 | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT06153693 |
| Placebo | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT06153693 |
| lorundrostat Dose 2 | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT06153693 |
| lorundrostat Dose 1 | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT06153693 |
| Placebo | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT06153693 |
| lorundrostat Dose 2 | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT06153693 |
| lorundrostat Dose 1 | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT06153693 |
| Placebo | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT06153693 |
| lorundrostat Dose 2 | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT06153693 |
| lorundrostat Dose 1 | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT06153693 |
| Placebo | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT06153693 |
| lorundrostat Dose 2 | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT06153693 |
| lorundrostat Dose 1 | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT06153693 |
| Placebo | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT06153693 |
| lorundrostat Dose 2 | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT06153693 |
| lorundrostat Dose 1 | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT06153693 |
| Placebo | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT06153693 |
| lorundrostat Dose 2 | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT06153693 |
| lorundrostat Dose 1 | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT06153693 |
| Placebo | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT06153693 |
| lorundrostat Dose 2 | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT06153693 |
| lorundrostat Dose 1 | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT06153693 |
| Placebo | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT06153693 |
| lorundrostat Dose 2 | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT06153693 |
| lorundrostat Dose 1 | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT06153693 |
| Placebo | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT06153693 |
| lorundrostat Dose 2 | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT06153693 |
| lorundrostat Dose 1 | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT06153693 |
| Placebo | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT06153693 |
| Lorundrostat | DRUG | Phase PHASE2 | Obstructive Sleep Apnea | COMPLETED | NCT06785454 |
| Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD | DRUG | Phase PHASE2 | Chronic Kidney Disease | COMPLETED | NCT06150924 |
| Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD | DRUG | Phase PHASE2 | Chronic Kidney Disease | COMPLETED | NCT06150924 |
| lorundrostat | DRUG | Phase PHASE3 | Hypertension | ACTIVE_NOT_RECRUITING | NCT05968430 |
| lorundrostat Dose 2 | DRUG | Phase PHASE3 | Hypertension | COMPLETED | NCT06153693 |
| lorundrostat Dose 1 | DRUG | Phase PHASE3 | Hypertension | COMPLETED | NCT06153693 |
| Placebo | DRUG | Phase PHASE2 | Obstructive Sleep Apnea | COMPLETED | NCT06785454 |
| MLS-101 (Part II) | DRUG | Phase PHASE2 | Hypertension, Renal | COMPLETED | NCT05001945 |
| Placebo (Part II) | OTHER | Phase PHASE2 | Hypertension, Renal | COMPLETED | NCT05001945 |
| Placebo (Part I) | OTHER | Phase PHASE2 | Hypertension, Renal | COMPLETED | NCT05001945 |
| MLS-101 (Part I) | DRUG | Phase PHASE2 | Hypertension, Renal | COMPLETED | NCT05001945 |